Latest Industry Insights

In this interview, we speak to Alon Ben-Noon, CEO and co-founder of Neurosense Therapeutics to hear about the impact their drug development strategy is having on the ALS field.

Developing and manufacturing biotherapeutics at scale requires thorough analysis of the active substance’s characteristics to ensure it fulfils both efficacy and safety requirements. Analytical technologies, such as mass spectrometry, are key tools adopted in this process.

We spoke to Neil Torbett, PhD, CEO of PhoreMost to learn more about “undruggable” targets and how the SITESEEKER® platform can identify these novel sites in the human proteome.

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.

Technology Networks spoke to Francisco Bizouarn, market development manager of the Digital Biology Group at Bio-Rad Laboratories, to find out how wastewater testing works and how it can anticipate a rise in cases of COVID-19 and the emergence of new variants.

In this interview, Lei Zhou, PhD, head of the Ocular Proteomics Platform at the Singapore Eye Research Institute, talks about the development of a novel diagnostic test to guide precision medicine to prevent dry eye in patients after laser eye surgery.

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?

Dr. Christian Landles highlights some of the progress made in recent years to improve our understanding of HD and its drivers.

Technology Networks had the pleasure of interviewing Sunny Himansu M.B.B.S., D.SM – associate director, infectious diseases at Moderna – to discuss the biotech company's pipeline, how a collaboration with IAVI aims to make mRNA-based preventives and therapeutics globally accessible and the future of mRNA in medicine.

In this interview, Dr. Daniel Hornburg discusses how engineered nanoparticles could help to bridge the gap between proteomics and genomics and transform cancer diagnostics.